Advertisement

Topics

Clinical Trials About "Looking Whales Insight Human Cancers" RSS

11:35 EDT 25th June 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Looking Whales Insight Human Cancers" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Looking Whales Insight Human Cancers" on BioPortfolio

We have published hundreds of Looking Whales Insight Human Cancers news stories on BioPortfolio along with dozens of Looking Whales Insight Human Cancers Clinical Trials and PubMed Articles about Looking Whales Insight Human Cancers for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Looking Whales Insight Human Cancers Companies in our database. You can also find out about relevant Looking Whales Insight Human Cancers Drugs and Medications on this site too.

Showing "Looking Whales Insight Human Cancers" Clinical Trials 1–25 of 9,200+

Relevant

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Subjects have a type of cancer that has been associated with an infection with a virus called human papilloma virus (HPV). The cancer has come back, has not gone away after standard treatment or the subject cannot receive standard treatment. The is a research study using special immune system cells called HPVST cells, a new experimental treatment. Investigators want to find out if they can use this type of treatment in patients with HPV-cancers. They have discovered a w...


Cognate Patient Care Insight Scale

Schizophrenia is a disease of young adults that affects 1% of the general population. According to numerous studies, it has been estimated that between 50% and 80% of patients with schizophrenia do not consider to have a mental disorder and are therefore not aware of their disorders. A poor degree of insight is associated with poor compliance, a higher number of re-hospitalizations, altered social and relational functioning, and a higher number of suicides and violent behaviors...

Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

Minnelide, a water-soluble disodium salt variant of triptolide, is a diterpenoid heat shock protein 70 (HSP70) inhibitor. Studies using AML cell lines, primary patient samples, and mouse transplant models demonstrate that Minnelide has potent cell killing effects. Minnelide has already been developed for human use and given to patients in a phase I trial for gastrointestinal (GI) cancers. Given the clinical safety profile and preliminary activity described in human GI cancers, ...


Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will include monotherapy expansion cohorts in advanced solid and hematologic cancers to further examine SRF231 as monotherapy (100 patients total).

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum- tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose. The primary objective of Phase 1B is to estimate the efficacy of KITE-439 in human leukocyte antigen (HLA)-A*02:01+ adults with relapsed/refractory human papillomavirus (HPV)16+ cancers.

An Algorithm Driven Sepsis Prediction Biomarker

A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated. Specifically, InSight is compared with a well established severe sepsis detector in the UCSF electronic health record (EHR).

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

First in human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), administered alone in patients with previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor II) receptor. The primary objective of the study is to determine the GM102 recommended dose.

ACTolog in Patients With Solid Cancers

The ACTolog clinical trial IMA101-101 is a first-in-human trial for the ACTolog concept targeting patients with advanced stage solid cancers depending on the expression of ACTolog targets within their tumors. In the IMA101-101 trial, a patient's tumor is first biomarker tested for the expression of ACTolog targets ("antigen warehouse"). Only if the individual tumor is positive for at least one ACTolog target, the patient will be enrolled in the trial.

Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial

The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive Training for Psychosis" (MCT), in relation to each other, and in relation to "Treatment As Usual" (TAU). It is hypothesized that at the end of therapy, compared to "Treatment As Usual", patients undergoing whether (IEP) or (MCT) will display a significant ...

The Psychobiological Effects of Participation in a One-Month Insight Meditation Retreat

The purpose of this study was to examine how participation in a 1 month intensive Insight (vipassana) Meditation retreat (a) affects biological markers of cellular aging, social affiliation, and inflammation, which are important for physical health, longevity, and behavior, and (b) to relate observed biological changes to baseline levels and changes in psychological traits, which may underlie improvements in personal adaptive functioning.

9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in > 70%, approximately, of all cervical cancers. Recently, Merck's HPV vaccine Gardasil® [quadrivalent human papillomavirus (HPV-6,11,16,18 L1 VLP) recombinant vaccine] has been approved by the FDA for prevention of genital tract cancers and pre-cancers and geni...

Video as a Tool to Improve Insight in Schizophrenia

The deficit of awareness of pathology (or insight) is a common symptom in patients with schizophrenia and has a negative impact on the prognosis of the disease. Current treatments aren't effective enough on this symptom (Pijnenbord et al., 2013). Previous studies have shown a positive impact of videos of patients themselves on insight but they lacked power (Davidoff et al., 1998 ; Vikram et al., 2008 ; David et al., 2012). This technique needs more investigation. Our study aim...

Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients

The human papilloma virus (HPV) is known to be an important cause of cervical and anal cancers. Studies on patients who have received a solid organ transplant (such as a liver or kidney transplant) have suggested the risk of HPV-related cancers may be higher in this population. The HPV vaccine, Gardasil®, has been approved for use in males and females by Health Canada. In studies on healthy subjects this vaccine is nearly 100% effective at preventing infections from HPV seroty...

Repeatability and Reproducibility of Insight VHF Digital Ultrasound

The purpose of this study is to evaluate the repeatability and reproducibility of corneal (including corneal, epithelial, stromal, and LASIK flap thickness) and anterior segment measurements using the Insight very high-frequency digital ultrasound arc-scanner, and compare corneal and epithelial thickness measurements to those obtained using OCT.

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.

A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

This study will evaluate the safety, tolerability, and pharmacokinetics of BTRC4017A in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Assessment of Blood Glucose Monitoring Devices With New Insight Features

To investigate whether novel insight features in new BGMs can improve glycemic control.

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.

Gardasil Knowledge

Human papillomavirus (HPV) is the most common viral genital tract infection. The majority of women and men who are sexually active will be exposed to a strain or strains of the virus. While there are hundreds of viral strains, high risk strains are associated cervical and oral cancers. According to the Centers for Disease Control (CDC), between 2008 and 2012 there were 38,793 deaths attributed to HPV related cancers. Vaccinations were created in an attempt to prevent infection ...

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of CC-95251 in subjects with advanced solid cancers.

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of CC-95251 in subjects with advanced solid cancers.

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every three weeks. Patients with tumor types likely to express NaPi2b will be enrolled. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity.

Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers

The goal of this clinical research study is to learn if the combination of MEDI0457 and durvalumab can help to control cancers related to the Human Papilloma Virus (HPV). The safety of this combination therapy will also be studied. MEDI0457 is given using a procedure called electroporation, or EP. EP is the delivery of low-voltage electric pulses to the muscle tissue after injection of the MEDI0457. EP is designed to make MEDI0457 more effective. This is an investigatio...


More From BioPortfolio on "Looking Whales Insight Human Cancers"

Advertisement
Quick Search
Advertisement
Advertisement